Arena Pharmaceuticals is focused on developing novel, small molecule drugs with optimized receptor pharmacology and pharmacokinetics designed to deliver broad clinical utility across several therapeutic areas. Arena’s proprietary pipeline includes potentially first- or best-in-class programs. Its most advanced investigational clinical programs are ralinepag (APD811) which will be commencing a Phase 3 program for pulmonary arterial hypertension (PAH) and etrasimod (APD334) in Phase 2 for a broad range of immune and inflammatory conditions. Arena is also evaluating APD371 in Phase 2 for the treatment of pain associated with Crohn’s disease. In addition, Arena has collaborations with the following pharmaceutical companies: Everest Medicines Limited (Greater China and limited other regions for ralinepag and etrasimod), Axovant Sciences (nelotanserin – Phase 2), Boehringer Ingelheim International GmbH (undisclosed – preclinical) and Eisai Co., Ltd. and Eisai Inc. (Belviq® – marketed product).